Onconetix, Inc.
ONCOOnconetix, Inc.
NASDAQ
Healthcare
Biotechnology
$1.48
-0.40(-21.1%)
52W $1.49 – $39.45
AI-generated
Onconetix, Inc.
Revenue breakdown: Development Service (68.2%), Other Revenues (17.6%), Product Sales (14.2%).
$5MMkt Cap
$496.3KRev TTM
-$9MNI TTM
-0.0xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 12, 2026Onconetix, Inc. (ONCO) reported FY 2025 revenue of $815K, down 67.7% from $2.5M in 2024, primarily due to completion of a non-recurring development services contract with Immunovia, partially offset by $0.6M license revenue from a new agreement. Gross profit was $633K (77.6% margin), improved from $1.1M (41.8% margin) due to lower cost of revenue tied to services. Net loss narrowed...
What Changed Recently
Fundamentals
How The Business Makes Money
Revenue by Segment
Development Service68.2%($5M)
Other Revenues17.6%($1M)
Product Sales14.2%($949.7K)
License0%($1)
Revenue by Geography
European Union65%($6M)
CH32.5%($3M)
US1.3%($126.2K)
Non European Union0.9%($85.2K)
GB0.4%($42.6K)
Analyst View
Company Profile
CIK0001782107
ISINUS68237Q2030
CUSIP68237Q203
Phone513 620 4101
Address201 East Fifth Street, Cincinnati, OH, 45202, US
SEC EDGAR